Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial

BACKGROUND: Neratinib has efficacy in central nervous system (CNS) metastases from HER2‐positive metastatic breast cancer (MBC). We report outcomes among patients with CNS metastases at baseline from the phase III NALA trial of neratinib plus capecitabine (N + C) versus lapatinib plus capecitabine (...

Descripción completa

Detalles Bibliográficos
Autores principales: Hurvitz, Sara A., Saura, Cristina, Oliveira, Mafalda, Trudeau, Maureen E., Moy, Beverly, Delaloge, Suzette, Gradishar, William, Kim, Sung‐Bae, Haley, Barbara, Ryvo, Larisa, Dai, Ming‐Shen, Milovanov, Vladimir, Alarcón, Jesús, Kalmadi, Sujith, Cronemberger, Eduardo, Souza, Cristiano, Landeiro, Luciana, Bose, Ron, Bebchuk, Judith, Kabbinavar, Fairooz, Bryce, Richard, Keyvanjah, Kiana, Brufsky, Adam M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Inc. 2021
Materias:
Breast Cancer
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342591/
https://www.ncbi.nlm.nih.gov/pubmed/34028126
http://dx.doi.org/10.1002/onco.13830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8342591/
https://www.ncbi.nlm.nih.gov/pubmed/34028126
http://dx.doi.org/10.1002/onco.13830

Ejemplares similares